Status: *EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

ANNEX

In Annex I to Directive 91/414/EEC the following rows are added at the end of the table:

No	Common name, identification numbers	IUPAC name	Purity[a]	Entry into force	Expiration of inclusion	Specific provisions
‘192	Tritosulfuron CAS No 142469-14-5 CIPAC No 735	1-(4-methoxy-6-trifluoromethyl-1,3,5-triazin-2-yl)-3-(2-trifluoromethyl-benzenesulfonyl)-urea	≥ 960 g/kg The following manufacturing impurity is of toxicological concern and must not exceed a certain amount in the technical material: 2-Amino-4-methoxy-6-(trifluormethyl)-1,3,5-triazine: <0,2 g/kg	1 December 2008	30 November 2018	PART A Only uses as herbicide may be authorised. PART B For the implementation of the uniform principles of Annex VI, the conclusions of the review report on tritosulfuron, and in particular Appendices I and II thereof, as finalised in the Standing Committee on the Food

a Further details on identity and specification of active substances are provided in the review report.

Status: *EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

						Chain and Animal Health on 20 May 2008 shall be taken into account. In this overall assessment Member States must pay particular attention to: — the potential for groundwater contamination, when the active substance is applied in regions with vulnerable soil and/or climatic conditions, — the protection of aquatic organisms, — the protection of small mammals.

a Further details on identity and specification of active substances are provided in the review report.

Status: *EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

						Conditions of use shall include risk mitigation measures, where appropriate.’

a Further details on identity and specification of active substances are provided in the review report.